Clinical Trials Directory

Trials / Completed

CompletedNCT06661252

Evaluation of Nasal Biomarkers for Objective Assessment of Disease Severity in Respiratory Disorders

Status
Completed
Phase
Study type
Observational
Enrollment
111 (actual)
Sponsor
Diag-Nose Medical Pty Ltd · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Accepted

Summary

This research study is an observational, single site study quantifying expression of biomarkers of respiratory disease in nasal fluid using the ABEL microsampler device. The primary objective of this study is to compare biomarker expression between healthy controls and participants with respiratory disorders such as chronic obstructive pulmonary disorder (COPD), hayfever, chronic sinusitis, asthma and rhinitis.

Conditions

Interventions

TypeNameDescription
DEVICEABEL microsampler deviceThe ABEL microsampler device will be used to collect nasal fluid samples for biomarker analysis.

Timeline

Start date
2025-01-08
Primary completion
2025-11-25
Completion
2025-11-25
First posted
2024-10-28
Last updated
2026-04-13

Locations

1 site across 1 country: Australia

Source: ClinicalTrials.gov record NCT06661252. Inclusion in this directory is not an endorsement.

Evaluation of Nasal Biomarkers for Objective Assessment of Disease Severity in Respiratory Disorders (NCT06661252) · Clinical Trials Directory